RP L102

Drug Profile

RP L102

Alternative Names: RP L102; RP-L02

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CIEMAT
  • Developer CIEMAT; Rocket Pharmaceuticals
  • Class Antianaemics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Fanconi's anaemia

Most Recent Events

  • 18 May 2018 Interim safety and efficacy data from a phase I/II trial in Fanconi anaemia released by Rocket Pharmaceuticals
  • 17 May 2018 Rocket Pharmaceuticals and Stanford University School of Medicine agree to co-develop gene therapies in USA for Fanconi's anaemia
  • 17 May 2018 Rocket Pharmaceuticals and Stanford University School of Medicine plan a registrational clinical trial for Fanconi's anaemia in USA, in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top